ArticleInternational journal of women's dermatology2026
Recognizing and managing linear morphea in a pediatric patient with skin of color.
Article in International journal of women's dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linear morphea is the most prevalent subtype of morphea in pediatric patients and poses a significant clinical concern because of its potential to involve deeper tissues, including muscle, fascia, and bone. If not identified and treated promptly, this can result in long-term complications such as joint contractures, limb length discrepancies, and functional impairment. Diagnosing and managing morphea in children with skin of color presents unique challenges, as hallmark inflammatory signs like erythema may be less visible or absent altogether, leading to delays in diagnosis and difficulties in monitoring disease activity. In darker skin tones, active lesions may instead present as hyperpigmented or hypopigmented patches, which can mimic other common pediatric dermatoses. These diagnostic limitations underscore the need for heightened clinical suspicion and tailored diagnostic strategies in this population. While consensus-based treatment algorithms exist for pediatric morphea, these guidelines are largely derived from studies in lighter skin types and do not address diagnostic and monitoring challenges unique to patients with skin of color. Additional research is needed to develop inclusive guidelines that address these gaps and improve long-term disease control. Herein, we present the case of linear morphea in a 5-year-old African American child, highlighting the diagnostic, therapeutic, and monitoring challenges specific to pediatric patients with skin of color.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.